Cancer grading and molecular profiling have become indispensable in the age of personalized therapeutics. Such evaluation requires tissue sampling, which is not always easy to perform, and often impractical for tracking therapeutic response and resistance. Imaging provides a non-invasive way to assess for treatment response, but typically relies on basic metrics such as size or volume, which is often an inaccurate. Our group aims to bridge this diagnostic gap between radiology and pathology through investigation of novel non-invasive MRI-based markers that can highlight loco-regional changes in metabolism, perfusion, and tumor marker expression. Our goal is to provide MRI-based radiogenomic profiles that more accurately reflects tumor treatment sensitivity or therapeutic resistance, translating to increased management precision.